Found 20 multiple myeloma trials
A listing of multiple myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The primary purpose of this research study is to obtain specimens (blood, bone marrow, and other tissues) for research about multiple myeloma and related diseases.
The objective of this exploratory observational cohort study is to obtain blood samples - and in some cases, bone marrow aspirate samples - from patients with multiple myeloma for study in the laboratory.
This study will examine whether adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help multiple myeloma patients survive longer. For patients who do not have minimum residual disease [MRD-negative], this study is also trying to determine if maintenance therapy should be stopped after …
Phase 2
Please refer to Protocol Section 4 Please refer to Protocol Section 4 Please refer to Protocol Section 4
Phase 2
The research study is being conducted to see if combining an investigational drug, called belantamab mafodotin, with standard-of-care autologous stem cell transplant and maintenance therapy in patients with myeloma can help reduce the amount of myeloma cells that can be detected in patients after transplant. We will also study if …
he purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
The purpose of this study is to see if JNJ-68284528 is safe and useful for treating patients with relapsed or refractory multiple myeloma.
We are doing this study to see if CAR T-cell therapy (bb2121) and maintenance therapy with the drug lenalidomide can help delay multiple myeloma from coming back.
Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma. We would like to rely on WCG as the IRB of record for this study.
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
1 - 10 of 20
- 1
- 2
